Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Canal

Showing results (141-150 of 142) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 142 results.
British Journal of Cancer|March 10, 2005
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumoursJ P Delord, J Y Pierga, V Dieras, et al.
Bulletin Du Cancer|January 26, 1999
[Analysis of hematopoietic growth factor prescriptions in 19 french cancer centers]L Gautié, P Canal, A Menguy, et al.
Pageof 15

Showing results (141-150 of 142) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 142 results.
British Journal of Cancer|March 10, 2005
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumoursJ P Delord, J Y Pierga, V Dieras, et al.
Bulletin Du Cancer|January 26, 1999
[Analysis of hematopoietic growth factor prescriptions in 19 french cancer centers]L Gautié, P Canal, A Menguy, et al.
Pageof 15